- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:57 | The observation status for Guard Therapeutics International AB (publ) is removed | 48 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to substantial uncertainty regarding the issuer or the... ► Artikel lesen | |
| 16:30 | Guard Therapeutics International AB: Guard Therapeutics Completes Reverse Takeover of Disruptive Pharma and Executes In-Kind Share Issue | 156 | GlobeNewswire (Europe) | 27 July 2026 - Guard Therapeutics International AB (publ) (to be renamed Disruptive Pharma AB (publ)) ("Guard Therapeutics" or the "Company") today announces that the reverse takeover (RTO) of Disruptive... ► Artikel lesen | |
| 16.07. | Guard Therapeutics International AB: Guard Therapeutics Receives Conditional Approval for Continued Listing on Nasdaq First North Growth Market and Publishes Company Description | 94 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today received conditional approval from Nasdaq Stockholm ("Nasdaq") for the continued listing of the Company's... ► Artikel lesen | |
| 11.06. | The observation status for Guard Therapeutics International AB (publ) is updated | 165 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to information that the Company's board of directors had... ► Artikel lesen | |
| 10.06. | Guard Therapeutics International AB: Guard Therapeutics has entered into a conditional agreement for a reverse takeover with Disruptive Pharma | 235 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all... ► Artikel lesen | |
| 10.04. | The observation status for Guard Therapeutics International AB (publ) is updated | 266 | GlobeNewswire | On December 11, 2025, the shares in Guard Therapeutics International AB (publ) (the "Company") were given observation status with reference to information that the Company's board of directors had... ► Artikel lesen | |
| 09.04. | Guard Therapeutics International AB: Guard Therapeutics provides information regarding observation status on Nasdaq First North Growth Market | 201 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement... ► Artikel lesen | |
| 31.03. | Guard Therapeutics International AB: Guard Therapeutics provides update on strategic review | 244 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides an update regarding the strategic review that was announced in December 2025.
The Company has now completed... ► Artikel lesen | |
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 21.02. | Guard Therapeutics International AB Q4 Loss Decreases | 7 | RTTNews | ||
| 05.02. | Guard Therapeutics International AB: Guard Therapeutics Announces Changes to the Company's Management Team | 374 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announces changes to the company's management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review... ► Artikel lesen | |
| 05.02. | Guard Therapeutics International AB: Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review | 341 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides a status update regarding the strategic review that the Company announced through a press release on... ► Artikel lesen | |
| 15.01. | Guard Therapeutics International AB: Guard Therapeutics Partners in EU Consortium For Alport Syndrome | 573 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research... ► Artikel lesen | |
| 11.12.25 | Guard Therapeutics International AB (publ) receives observation status | 291 | GlobeNewswire | On December 4, 2025, Guard Therapeutics International AB (publ) (the "Company") issued a press release with information that the Board of Directors of the Company had resolved to commence an exploratory... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Explores Strategic Alternatives | 287 | GlobeNewswire (Europe) | Guard Therapeutics (publ) ("Guard" or the "Company") today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Provides Assessment of Full POINTER Study Results | 279 | GlobeNewswire (Europe) | Guard Therapeutics (public) ("Guard" or "the Company") today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery.... ► Artikel lesen | |
| 26.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study | 682 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 337 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen | |
| 11.09.25 | Guard Therapeutics International AB: Guard Therapeutics announces completion of data collection in Phase 2b POINTER study | 826 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery... ► Artikel lesen | |
| 21.08.25 | Guard Therapeutics International AB: Guard Therapeutics publishes interim report January-June 2025 | 292 | GlobeNewswire (Europe) | The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study - ahead of schedule. The positive final safety review reinforces confidence in the trial... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,88 | -2,18 % | Novonesis Q1 Net Profit Rises, Net Sales Up 7% Organically; Backs FY26 Outlook | BRUSSELS (dpa-AFX) - Novonesis A/S (NVZMF.PK, NSIS_B.CO, NSIS-B.CO, NVZMF, NSIS-B) Tuesday said that its first quarter net profit rose from last year, helped by good performances by the Food... ► Artikel lesen | |
| GENMAB | 252,50 | -0,36 % | Genmab A/S and AbbVie: Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial and was not met Genmab A/S(Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,790 | -2,57 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,210 | -2,78 % | Profitieren Sie von den Patenten und technologischen Schutzmauern von SAP, MustGrow Biologics und TSMC | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. In einer Ära, in der Geschäftsmodelle schneller kopiert werden als Kaffee am Morgen, entsteht der wahre Wettbewerbsvorteil nicht mehr... ► Artikel lesen | |
| VERICEL | 40,000 | +0,50 % | Vericel Corporation: Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,170 | +4,33 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| FAETH THERAPEUTICS | 29,770 | +7,24 % | Faeth Therapeutics, Inc. - 8-K, Current Report | ||
| BIOXCEL THERAPEUTICS | 0,792 | +6,17 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| REGENXBIO | 9,250 | +8,04 % | Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments | ||
| AKEBIA | 1,057 | -1,95 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Strengthens Vafseo (vadadustat) Patent Portfolio | CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,700 | +3,82 % | Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 8,900 | +1,71 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 11,750 | -1,59 % | Corvus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| REVANCE THERAPEUTICS | - | - | Revance taps dancer Julianne Hough to choreograph social media push for Botox rival | ||
| CARTESIAN THERAPEUTICS | 6,750 | +2,27 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases | WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans... ► Artikel lesen |
GUARD THERAPEUTICS INTERNATIONAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.